Dianthus Therapeutics (DNTH) Expected to Release Earnings on Thursday

Key Points

• Dianthus Therapeutics is expected to report Q3 2026 results after market close on Thursday, November 5, with analysts forecasting a loss of $0.9445 per share and revenue of $0.46 million.
• The company reported a larger-than-expected loss in the previous quarter, while analysts project full-year and next-year losses of $3.81 and $4.74 per share, respectively.
• Despite recent insider selling and volatile trading, analysts maintain a consensus “Buy” rating with an average price target of $128.54, above the stock’s recent $82.31 price.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Dianthus Therapeutics to announce earnings of ($0.9445) per share and revenue of $0.46 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, analysts expect Dianthus Therapeutics to post ($3.81) EPS for the current fiscal year and ($4.74) EPS for the next fiscal year.

Dianthus Therapeutics Trading Up 3.5%

Shares of NASDAQ:DNTH opened at $82.31 on Thursday. The stock has a market capitalization of $4.51 billion, a PE ratio of -19.83 and a beta of 1.35. Dianthus Therapeutics has a 1 year low of $32.28 and a 1 year high of $117.88. The firm has a fifty day moving average price of $93.92 and a 200 day moving average price of $84.17.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DNTH. Roth Capital assumed coverage on Dianthus Therapeutics in a research note on Tuesday. They set a "buy" rating and a $113.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, Truist Financial upped their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $128.54.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CAO Edward Carr sold 20,000 shares of Dianthus Therapeutics stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the sale, the chief accounting officer directly owned 20,000 shares of the company's stock, valued at $2,027,600. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Adam Veness sold 16,167 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president owned 3,833 shares in the company, valued at $423,086.54. This represents a 80.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 242,429 shares of company stock valued at $26,118,913 over the last quarter. Company insiders own 3.02% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company's research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus' lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.